1. Text: | Print|

      Pharma giant GSK investigated for bribery

      2013-07-12 10:49 Global Times Web Editor: qindexing
      1

      Executives from global pharmaceutical giant GlaxoSmithKline's China branch are being investigated for suspected bribery, the Ministry of Public Security said on Thursday, signaling China's latest efforts to regulate this industry.

      GlaxoSmithKline (GSK) has bribed government officials, pharmaceutical industry associations, hospitals and doctors directly or indirectly in order to increase sales or raise drug prices, the ministry said in a statement posted on its official website, adding the case is still under investigation.

      Evidence shows that some senior GSK executives were involved in bribery through travel agencies, and were also involved in tax violations, according to the statement.

      But the ministry didn't reveal the number or the nationality of executives involved in the investigation.

      "GSK is willing to cooperate with relevant authorities in the investigation," the company said in a statement sent to the Global Times on Thursday.

      The company takes seriously all reports of bribery and corruption, and will continue to supervise business activities to ensure they are compliant with GSK rules, and quickly take action in case of a breach, GSK said.

      Many companies are doing the same thing but haven't been caught, an industry insider who used to work in a large multinational pharma company, told the Global Times on condition of anonymity, adding such cases are normally triggered by a whistleblower who could be an unsatisfied employee, a competitor, or even a doctor.

      "The company will most likely face a large fine, and the personnel involved could even face criminal charges if convicted," he said.

      "We are paying close attention to the progress of this matter," the R&D-based Pharmaceutical Association Committee, an organization of foreign pharmaceutical companies in China, said when reached by the Global Times, otherwise refusing to comment.

      Multinational pharmaceutical companies usually have strict internal controls, such as limits on gift value to doctors, entertainment fees, or a number of days limit for organizing overseas trips for doctors so that gift giving or entertaining is not defined as bribery, the industry insider said.

      However, practices such as kickbacks on doctor's prescriptions or gifts to officials to ensure better bargains or get their products onto the official government reimbursement list do happen due to fierce competition from domestic firms, he said.

      Sometimes such practices are inevitable, "without doing the same, the company will lose sales and market share," he said, claiming that it is common practice not only in China but also in the US where the Foreign Corrupt Practices Act inflicts penalties even on companies who pay bribes overseas.

      International pharmaceutical giants Eli Lilly in 2011 and Pfizer in 2012 were charged for improper or illegal payments their subsidiaries made to win business in countries including China, and paid multi-million dollar sums in settlement, according to the US Securities and Exchange Commission.

      Apart from pharmaceutical companies, IBM, Avon, and Alcatel-Lucent have also been involved in bribery cases in China in recent years.

      "China provides many preferential policies toward foreign companies in order to attract foreign direct investment, however, it weakened supervision of and regulation on these companies. Investigating GSK serves as a warning, which is good for regulating the industry," said Xu Lingni, a healthcare analyst at CIC Industry Research.

      This case will have a major impact on the industry, and drug makers are expected to tighten control on fees and expenditures, strengthen training for sales staff, and be more legally compliant, Zhong Hongyue, a healthcare sector analyst at consulting firm Frost & Sullivan, told the Global Times.

      China has seen more violations by foreign companies in recent years, partly due to the business circumstances and a lack of strict regulation, Zhang Wang, director of the Social Responsibility Research Center for Chinese Listed Companies, told the Global Times on Thursday.

      International pharmaceutical companies regard China as an increasingly important market. IMS Health, a healthcare market intelligence service provider, expects China to overtake Japan as the world's second largest drug market after the US by 2016.

      Comments (0)
      Most popular in 24h
        Archived Content
      Media partners:

      Copyright ©1999-2018 Chinanews.com. All rights reserved.
      Reproduction in whole or in part without permission is prohibited.

      主站蜘蛛池模板: 亚洲爆乳无码一区二区三区| 亚洲短视频男人的影院| 亚洲一级黄色大片| 亚洲高清乱码午夜电影网| 一级做受视频免费是看美女| 亚洲一区二区三区国产精华液| 国产视频精品免费| 亚洲AV第一成肉网| 一级看片免费视频| 精品国产亚洲一区二区在线观看| 一区二区三区在线免费观看视频 | 在线综合亚洲欧洲综合网站 | 中文字幕亚洲免费无线观看日本 | 亚洲色欲色欲www在线播放| 永久黄网站色视频免费直播| 亚洲6080yy久久无码产自国产| 永久黄网站色视频免费观看| 日日狠狠久久偷偷色综合免费| 亚洲福利精品一区二区三区| 成全动漫视频在线观看免费高清版下载| 在线观看亚洲天天一三视| 色欲色香天天天综合网站免费| 亚洲毛片在线免费观看| 四虎影院在线免费播放| jizz中国免费| 老司机亚洲精品影院无码 | 中文字幕av免费专区| 青青草原精品国产亚洲av| 影音先锋在线免费观看| 深夜特黄a级毛片免费播放| 亚洲大成色www永久网站| 4虎永免费最新永久免费地址| 亚洲不卡av不卡一区二区| 亚洲高清中文字幕免费| 视频一区二区三区免费观看| 亚洲精品乱码久久久久久中文字幕| 最近中文字幕完整免费视频ww| 亚洲精品理论电影在线观看| 亚洲熟女少妇一区二区| 免费a级毛片无码a∨蜜芽试看| 色老头综合免费视频|